Insulin-like growth factor I and Alzheimer's disease: Therapeutic prospects?

45Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The search for a cure of Alzheimer's dementia is restless. In recent years, unexpected epidemiological data showing a protective effect of anti-inflammatory and cholesterol-lowering drugs gave way to clinical trials with these compounds. Now, a newly described mechanism indicating that brain amyloid clearance is modulated by serum insulin-like growth factor I may also lead to new trials with this growth factor. Insulin-like growth factor I is an abundant circulating hormone with potent central actions whose levels in serum appear to be altered in Alzheimer's patients. Amyloid clearance, a potential therapeutic target in Alzheimer's disease was mostly neglected until recent antiamyloid therapies proved to involve a peripheral amyloid sink. Although more work in animal models are required, the evidence available strongly indicates that insulin-like growth factor I therapy in Alzheimer's dementia may be addressing pathogenic processes.

Cite

CITATION STYLE

APA

Carro, E., & Torres-Aleman, I. (2004, January). Insulin-like growth factor I and Alzheimer’s disease: Therapeutic prospects? Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.4.1.79

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free